Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide plus lopinavir/ritonavir in adults with HIV-1 after failure of standard first-line ART
ChiCTR-TRC-14004276Phase 3Completed
- Sponsor
- Beijing YouAn Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of albuvirtide and lopinavir + ritonavir in Human immunodeficiency virus infection type 1 and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoints: Safety indexes and HIV RNA. Started Jan 2014; status: completed.
02
Drugs
albuvirtidelopinavir + ritonavir
03
Conditions
Human immunodeficiency virus infection type 1acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR-TRC-14004276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004276.